A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease

Inclusion Criteria: * 55-80 years old (including 55 and 80), male or female, sufficient vision, hearing and general health to complete the follow-up and assessment; * Patients who were diagnosed with AD according to the DSM-IV; * MMSE score \> 10 and ≤ 24; * HAMA score \> 8; * HAMD score ≤ 7; * Brain CT or MRI supports the diagnosis of AD; * Provide written informed consent by the patient himself and his family member or guardian. Exclusion Criteria: * Dementia from any other cause; * Brain MRI showed that the diameter of hyperintense lesions in T2-FLAIR sequences were larger than 5mm; * Patients with significant cardiac, pulmonary, hepatic, renal, or hematologic disease; * Any primary neurologic or psychiatric disease other than AD; * Mental disorders due to substance abuse; * Participation in other clinical studies within the last 30 days; * History of alcohol or substance abuse or dependence within the past year; * Pregnant or breastfeeding, or of child-bearing potential during the study.